NCT04865393View on ClinicalTrials.gov

Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

37

Participants

Timeline

Start Date

June 8, 2021

Primary Completion Date

December 1, 2021

Study Completion Date

December 6, 2021

Conditions

Renal Impairment

Interventions

DRUG

SPR206

SPR206 100 mg single-dose IV infused over 1 hour

Trial Locations (2)

1010

Medical Facility, Auckland

8011

Medical Facility, Christchurch

Sponsors

Lead Sponsor

Spero Therapeutics

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Spero Therapeutics

INDUSTRY